FORMYCON AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.35 EUR | +7.29% |
|
+11.42% | -17.82% |
| 25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 822M | - | |||||
| 47.9B | - | |||||
| 41.42B | ||||||
| 40.7B | ||||||
| 28.92B | ||||||
| 25.55B |
- Stock Market
- Equities
- FYB Stock
- Charts Formycon AG
- Sector Chart